Analysis Personal Paper
Regulation—the real threat to clinical researchBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a1732 (Published 16 October 2008) Cite this as: BMJ 2008;337:a1732
- Analysis Published: 22 May 2009; BMJ 338 doi:10.1136/bmj.b1893
- Letter Published: 10 December 2008; BMJ 337 doi:10.1136/bmj.a2917
- Education And Debate Published: 29 July 2004; BMJ 329 doi:10.1136/bmj.329.7460.286
- Letter Published: 10 December 2008; BMJ 337 doi:10.1136/bmj.a2918
- Letter Published: 10 December 2008; BMJ 337 doi:10.1136/bmj.a2914
- Letter Published: 07 April 2005; BMJ 330 doi:10.1136/bmj.330.7495.847
- Editorial Published: 05 July 2007; BMJ 335 doi:10.1136/bmj.39201.508692.2C
- Letter Published: 10 December 2008; BMJ 337 doi:10.1136/bmj.a2916
- Letter Published: 10 December 2008; BMJ 337 doi:10.1136/bmj.a2920
- Editor's Choice Published: 11 December 2008; BMJ 337 doi:10.1136/bmj.a2986
- Letter Published: 10 December 2008; BMJ 337 doi:10.1136/bmj.a2919
- Trump chooses Obamacare opponent to lead Health and Human ServicesBMJ November 30, 2016, 355 i6469; DOI: https://doi.org/10.1136/bmj.i6469
- Drug firms need to tackle affordabilityBMJ November 14, 2016, 355 i6096; DOI: https://doi.org/10.1136/bmj.i6096
- World Medical Association’s tainted president, Ketan DesaiBMJ November 10, 2016, 355 i5867; DOI: https://doi.org/10.1136/bmj.i5867
- Cancer drugs, survival, and ethicsBMJ November 09, 2016, 355 i5792; DOI: https://doi.org/10.1136/bmj.i5792
- WHO refers $29m Oxford research project to GMC for misconductBMJ November 07, 2016, 355 i5971; DOI: https://doi.org/10.1136/bmj.i5971
- Impact of NCI-Mandated Scientific Review on Protocol Development and Content
- The effect of the neonatal Continuous Negative Extrathoracic Pressure (CNEP) trial enquiries on research in the UK
- Streamlined research governance: are we there yet?
- Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical Research
- How the NHS research governance procedures could be modified to greatly strengthen clinical research
- Over-regulation, Russian style
- The good, the bad and the ugly red tape of biomedical research: How could regulators lower bureaucratic hurdles in clinical research without compromising the safety of patients?
- A regulator writes
- Time for patients to speak out?
- Barrier is impossible to leap
- A UK problem
- Can anyone beat my delays?
- Regulation has run amok
- Research is no longer attractive